May 2019

FIRST MEDICINAL CANNABIS TRIAL TO TREAT TOURETTE’S SYNDROME BRINGS HOPE TO AUSTRALIAN PATIENTS

Chris Wright, Brisbane local who was diagnosed with Tourette’s syndrome at the age of 12 is one of the first patients recruited for the trial run by Brisbane’s Wesley Medical Research. The trial aims to assess the effects of medicinal cannabis on symptoms such as uncontrollable physical and/or verbal ticks. Read the article here.

We’re thrilled to announce we have received our export licence from the Drug Control Section of the ODC (Office of Drug Control). We’re firmly on course to continue to lead the way and be the first medicinal cannabis company in Australia to export cannabis flower to the EU since export was legalised in 2018.

READ MORE >

We have successfully passed three consecutive TGO93 and TGO100 tests on our medicinal cannabis products since our first commercial harvest at the end of 2019.

READ MORE >

One of ANTG’s proprietary medicinal cannabis strains, EVE Cannabis Indica, has been listed on the Australian Register of Therapeutic Goods (ARTG). The ARTG is a reference of therapeutic goods that can lawfully be supplied in or exported from Australia.

READ MORE >

We are focused on research and development, partnering with leading scientists and medical institutions to develop cannabinoid medicines that offer safe and effective therapeutic benefits.

LEARN ABOUT ANTG HERE >